Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vital Therapies Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure, today announced the pricing of an underwritten public offering of 5,454,546 newly issued shares
View HTML
Toggle Summary Vital Therapies Provides Corporate Update and Announces Date of Third Quarter 2015 Financial Results
SAN DIEGO , Oct. 16, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today provided an update on its clinical development program.
View HTML
Toggle Summary Vital Therapies Outlines Plans for New Phase 3 Trial of ELAD(R) in Alcohol-Induced Liver Decompensation
SAN DIEGO, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today outlined plans for a possible new phase 3 clinical trial designed to confirm ELAD's safety and
View HTML
Toggle Summary Vital Therapies Announces Workforce and Cost Reduction Plans to Conserve Capital for a Possible New Clinical Trial
SAN DIEGO, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced a workforce reduction of approximately 30% and plans to institute across the board expense
View HTML
Toggle Summary Vital Therapies Announces Additional Data From VTI-208 Presented at Rostock Conference
SAN DIEGO, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced that additional data from its VTI-208 clinical trial were presented by two principal
View HTML
Toggle Summary Vital Therapies Announces That Topline Results of VTI-208 Fail to Achieve Primary or Secondary Endpoints of Improvement in Overall Survival Pre-Specified Exploratory Subset Analyses Suggest Efficacy Trends
SAN DIEGO , Aug. 21, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced that topline results from VTI-208, the Company's phase 3 randomized, controlled,
View HTML
Toggle Summary Vital Therapies Announces Second Quarter 2015 Financial Results and Provides Corporate Update
SAN DIEGO , July 30, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced results for the second quarter ended June 30, 2015 and provided a corporate update.
View HTML
Toggle Summary Vital Therapies Announces Second Quarter 2015 Financial Results Conference Call With Webcast Scheduled for Thursday, July 30, 2015
SAN DIEGO , July 27, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD ® , a cell-based therapy targeting the treatment of liver failure, will release its second quarter 2015 financial results after the market closes on Thursday, July 30,
View HTML
Toggle Summary Vital Therapies Announces Appointment of Former Medivation Chief Commercial Officer Cheryl Cohen to Its Board of Directors
SAN DIEGO , July 15, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced that Cheryl Cohen , the former Chief Commercial Officer of Medivation, Inc., has been
View HTML
Toggle Summary Vital Therapies Announces Poster Presentation at International Liver Transplantation Society Meeting Today in Chicago
SAN DIEGO , July 9, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, announced the presentation of a poster at the International Liver Transplantation Society's 21 st Annual
View HTML